天堂网亚洲,天天操天天搞,91视频高清,菠萝蜜视频在线观看入口,美女视频性感美女视频,95丝袜美女视频国产,超高清美女视频图片

ChemicalBook >> journal list >> Cancer discovery >>article
Cancer discovery

Cancer discovery

IF: 29.69
Download PDF

Brigatinib Outperforms Crizotinib as First-Line Therapy.

Published:1 February 2020 DOI: 10.1158/2159-8290.CD-NB2019-143 PMID: 31879274

Abstract

The latest results from the phase III ALTA-1L trial suggest that the ALK inhibitor brigatinib is superior to crizotinib in patients with untreated non-small cell lung cancer. Brigatinib yielded a longer progression-free survival, a higher objective response rate, and greater effectiveness against brain metastases-and was less detrimental to patients' quality of life.

Substances (2)

Related products
Procduct Name CAS Molecular Formula Supplier Price
Crizotinib 877399-52-5 C21H22Cl2FN5O 551 suppliers $5.00-$1963.50
Brigatinib 1197953-54-0 C29H39ClN7O2P 307 suppliers $5.00-$1504.50

Similar articles

IF:8.3

Cardiovascular risk associated with acarbose versus metformin as the first-line treatment in patients with type 2 diabetes: a nationwide cohort study.

Neural Regeneration Research Chia-Hsuin Chang, Yi-Cheng Chang,etc Published: 1 March 2015
IF:3

A comprehensive review on Brigatinib – A wonder drug for targeted cancer therapy in non-small cell lung cancer

Neural Regeneration Research Silky Bedi , Shah A. Khan ,etc Published: 1 September 2018